SHINGRIX DIN 02468425
Status: Marketed
Holder: GLAXOSMITHKLINE INC
Available to quote
Health Canada record
| Active ingredient(s) | VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN 50 MCG |
|---|---|
| Dosage form | Suspension |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BK VARICELLA ZOSTER VACCINES |
| Original market date | 02-Jan-2018 |
| Current status date | 02-Jan-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02570270 | SHINGRIX | GLAXOSMITHKLINE INC | Suspension | VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN 50 MCG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 19911 | 2017-10-13 | New Drug Submission (NDS) |